Department of Urology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Division of Experimental Oncology, URI, Urological Research Institute, Renal Cancer Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Lancet. 2016 Feb 27;387(10021):894-906. doi: 10.1016/S0140-6736(15)00046-X. Epub 2015 Aug 25.
The diagnosis and management of renal cell carcinoma have changed remarkably rapidly. Although the incidence of renal cell carcinoma has been increasing, survival has improved substantially. As incidental diagnosis of small indolent cancers has become more frequent, active surveillance, robot-assisted nephron-sparing surgical techniques, and minimally invasive procedures, such as thermal ablation, have gained popularity. Despite progression in cancer control and survival, locally advanced disease and distant metastases are still diagnosed in a notable proportion of patients. An integrated management strategy that includes surgical debulking and systemic treatment with well established targeted biological drugs has improved the care of patients. Nevertheless, uncertainties, controversies, and research questions remain. Further advances are expected from translational and clinical studies.
肾细胞癌的诊断和治疗已经发生了显著的变化。尽管肾细胞癌的发病率一直在增加,但生存率却有了显著的提高。随着对小而惰性癌症的偶然诊断越来越频繁,主动监测、机器人辅助肾部分切除术技术以及微创治疗(如热消融)变得越来越受欢迎。尽管在癌症控制和生存率方面取得了进展,但仍有相当比例的患者被诊断为局部晚期疾病和远处转移。一种综合管理策略,包括手术去瘤和系统治疗,以及已确立的靶向生物药物,已经改善了患者的治疗效果。然而,仍存在不确定性、争议和研究问题。进一步的进展预计将来自转化和临床研究。